Broker Wilsons Advisory has put lofty price targets on a clothing retailer and oncology biotech firm, predicting big things for both ASX stocks.
Broker Wilsons Advisory has put lofty price targets on a clothing retailer and oncology biotech, predicting big things for both ASX stocks.
It says Universal Store Holdings shares are trading well below those of its peers, while Clarity Pharma is likely to surge if a prostate cancer trial is successful.
Wilsons’ 12-month target prices for the two stocks are 48 per cent and 60 per cent higher (respectively) than their current level.
Youth apparel retailer UNI ‘attractive’
Wilsons Advisory has placed an Overweight rating on youth casual apparel retailer, Universal Store Holdings (ASX:UNI), with a 12-month target price of $4.22 (vs current price of $2.85).
Last week, the company told the market that it was on track to deliver record sales in FY23, and material growth in EBIT compared to FY22.
For the latest investment news, sign up here for free Stockhead daily newsletters
However, UNI acknowledged there were increasing signs of pressure in the youth market and its discretionary spending power.
Despite these tailwinds, Wilsons said it retains a favourable view of UNI given the retailer has an attractive store pipeline, and clear momentum from its brands, Perfect Stranger and CTC (Thrills).
Wilsons also believes UNI has a strong, experienced management team.
Valuation wise, UNI is trading on a PE ratio of around 9x, versus its peers’ ratio of around 12.8x.
“We therefore believe a premium is warranted due to UNI’s growth profile,” said Wilsons.
Overall, Wilsons believes UNI has an “attractive” product offering, a well aligned and experienced executive team, and attractive runways for growth in online, private label and physical store numbers.
“While macro conditions are volatile, UNI has a captive and relatively well capitalised customer base and a high ASP/Margin which sets it apart from peers,” the broker said.
MORE FROM STOCKHEAD: 60/40 strategy not dead, says UBS | Red Leaf a fan of ASX e-commerce stocks | Tech baron sold on Jayride
Prostate cancer trial key for Clarity
Wilsons Advisory also has an Overweight recommendation on oncology biotech Clarity Pharmaceuticals (ASX:CU6), with a 12-month price target of $1.22 (vs current price of $0.76).
Clarity announced last week that its SeCuRE prostate cancer trial was advancing to cohort 2 after the completion of cohort 1 dosing.
The clinical trial is studying the effects of Clarity’s 67Cu SAR-bisPSMA on patients with metastatic castrate-resistant prostate cancer (mCRPC).
Cohort 1 was completed in six participants at the lowest dose level of 4GBq, with no dose-limiting toxicities reported.
Wilsons said that was an extremely important result, as it represented the first safety data provided for 67Cu-SAR-bisPSMA, and hence in the prostate cancer population.
Visit Stockhead, where ASX small caps are big deals
Additionally, the cohort 1 results provide a potential positive read-through for the ongoing trial in neuroblastoma, which is currently assessing a higher dose of 67Cu-SARTATE.
Wilson said Clarity’s 67Cu-SAR-bisPSMA differs from others in development (for example: TLX-591, PNT2002), and on-the-market drug PLUVICTO.
PLUVICTO is undergoing supply issues, and as a result it’s believed Clarity has placed increased urgency on its trial.
“We anticipate that the trial will conclude around the end of CY24,” Wilsons said.
In April, Clarity’s exclusive 67Cu production partner, NorthStar, provided an update regarding the anticipated availability of 67Cu “within a few weeks”.
“The imminent confirmation of this supply is clearly a significant de-risking point for Clarity for future, larger clinical trials, and product commercialisation,” said Wilsons.
Clarity Pharma share price today:
This content first appeared on stockhead.com.au
The views, information, or opinions expressed in the interview in this article are solely those of the broker and do not represent the views of Stockhead.Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox. Click here